# Bioequivalence and Safety Study of Bevacizumab-biosimilar (RPH-001) Compared to Bevacizumab-innovator

> **NCT03131700** · PHASE1 · WITHDRAWN · sponsor: **TRPHARM**

## Conditions studied

- Healthy

## Interventions

- **BIOLOGICAL:** RPH001
- **BIOLOGICAL:** Avastin®

## Key facts

- **NCT ID:** NCT03131700
- **Lead sponsor:** TRPHARM
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2017-12
- **Primary completion:** 2018-01
- **Final completion:** 2018-01
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Decision of the Sponsor
- **Last updated:** 2018-04-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03131700

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03131700, "Bioequivalence and Safety Study of Bevacizumab-biosimilar (RPH-001) Compared to Bevacizumab-innovator". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03131700. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*